| 2021 |
| 03/29 | 1,508 | 1,508 | 1,456 | 1,471 | 0% | 151,900 | 449億5846万 | +2.44% |
| 03/26 | 1,455 | 1,496 | 1,455 | 1,471 | +1.87% | 92,900 | 449億5846万 | +2.65% |
| 03/25 | 1,442 | 1,462 | 1,429 | 1,444 | +0.14% | 115,600 | 441億3325万 | +0.84% |
| 03/24 | 1,508 | 1,509 | 1,419 | 1,442 | -6.18% | 187,400 | 440億7213万 | +0.56% |
| 03/23 | （IR情報）15:00 「リオナ錠(クエン酸第二鉄水和物)」の国内における鉄欠乏性貧血の効能追加承認取得及びプロモーション開始のお知らせ |
| 03/23 | 1,610 | 1,618 | 1,537 | 1,537 | -4.36% | 158,300 | 469億7563万 | +7.03% |
| 03/22 | （IR情報）15:00 新中期経営計画の策定について |
| 03/22 | 1,575 | 1,612 | 1,562 | 1,607 | +3.88% | 214,900 | 491億1506万 | +11.99% |
| 03/19 | 1,539 | 1,547 | 1,514 | 1,547 | +0.52% | 131,000 | 472億8126万 | +8.03% |
| 03/18 | 1,527 | 1,540 | 1,516 | 1,539 | +1.85% | 127,000 | 470億3676万 | +7.55% |
| 03/17 | 1,490 | 1,511 | 1,472 | 1,511 | +1.41% | 95,700 | 461億8099万 | +5.66% |
| 03/16 | 1,494 | 1,496 | 1,478 | 1,490 | +0.4% | 82,600 | 455億3916万 | +4.2% |
| 03/15 | （IR情報）11:00 GnRH アンタゴニスト「レルミナ錠（レルゴリクス）」子宮内膜症 第3相比較試験結果発表のお知らせ |
| 03/15 | 1,461 | 1,484 | 1,457 | 1,484 | +2.56% | 107,000 | 453億5578万 | +3.7% |
| 03/12 | 1,448 | 1,452 | 1,430 | 1,447 | +0.14% | 94,900 | 442億2494万 | +0.98% |
| 03/11 | 1,429 | 1,446 | 1,420 | 1,445 | +1.62% | 108,200 | 441億6382万 | +0.63% |
| 03/10 | 1,443 | 1,443 | 1,415 | 1,422 | +0.21% | 91,600 | 434億6086万 | -1.18% |
| 03/09 | 1,410 | 1,422 | 1,397 | 1,419 | +1.72% | 94,600 | 433億6917万 | -1.73% |
| 03/08 | 1,404 | 1,410 | 1,385 | 1,395 | +1.09% | 103,100 | 426億3566万 | -3.66% |
| 03/05 | 1,365 | 1,384 | 1,337 | 1,380 | +2.83% | 126,500 | 421億7721万 | -5.09% |
| 03/04 | （IR情報）16:00 「健康経営優良法人 ホワイト500」3年連続認定のお知らせ |
| 03/04 | 1,351 | 1,352 | 1,329 | 1,342 | -1.18% | 102,200 | 410億1581万 | -8.15% |
| 03/03 | 1,340 | 1,358 | 1,337 | 1,358 | +1.04% | 86,700 | 415億482万 | -7.56% |
| 03/02 | 1,358 | 1,366 | 1,337 | 1,344 | -0.3% | 95,200 | 410億7693万 | -9.07% |
| 03/01 | （IR情報）16:00 あすか製薬ホールディングス株式会社の新規上場承認に関するお知らせ |
| 03/01 | 1,342 | 1,350 | 1,336 | 1,348 | +0.67% | 100,100 | 411億9919万 | -9.29% |
| 02/26 | 1,331 | 1,355 | 1,329 | 1,339 | -0.74% | 156,300 | 409億2412万 | -10.31% |
| 02/25 | 1,365 | 1,367 | 1,346 | 1,349 | -0.74% | 144,600 | 412億2975万 | -10.13% |
| 02/24 | 1,400 | 1,403 | 1,359 | 1,359 | -3.69% | 184,300 | 415億3538万 | -9.76% |
| 02/22 | 1,410 | 1,426 | 1,393 | 1,411 | +0.36% | 143,000 | 431億2467万 | -6.74% |
| 02/19 | 1,407 | 1,417 | 1,389 | 1,406 | -1.75% | 132,500 | 429億7185万 | -7.44% |
| 02/18 | （IR情報）10:30 抗甲状腺剤「メルカゾール錠2.5mg」新発売のお知らせ |
| 02/18 | 1,480 | 1,480 | 1,427 | 1,431 | -3.96% | 153,600 | 437億3593万 | -6.23% |
| 02/17 | 1,500 | 1,506 | 1,486 | 1,490 | -0.73% | 116,200 | 455億3916万 | -2.87% |
| 02/16 | 1,526 | 1,526 | 1,500 | 1,501 | -1.31% | 116,100 | 458億7536万 | -2.53% |
| 02/15 | 1,531 | 1,534 | 1,517 | 1,521 | +0.4% | 88,700 | 464億8662万 | -1.49% |
| 02/12 | 1,532 | 1,533 | 1,508 | 1,515 | -1.56% | 90,600 | 463億324万 | -1.94% |
| 02/10 | 1,513 | 1,545 | 1,506 | 1,539 | +2.46% | 142,300 | 470億3676万 | -0.52% |
| 02/09 | 1,519 | 1,519 | 1,501 | 1,502 | -0.92% | 118,900 | 459億592万 | -2.97% |
| 02/08 | （IR情報）15:00 『2021年女性の健康週間丸の内キャリア塾スペシャルセミナー』への協賛について |
| 02/08 | （IR情報）15:00 リボミックとあすか製薬の共同研究に関する共同研究開発契約締結のお知らせ |
| 02/08 | 1,530 | 1,530 | 1,506 | 1,516 | -0.26% | 126,600 | 463億3380万 | -2.32% |
| 02/05 | 1,536 | 1,538 | 1,513 | 1,520 | +0.26% | 86,900 | 464億5606万 | -2.25% |
| 02/04 | 1,525 | 1,526 | 1,505 | 1,516 | -0.92% | 115,200 | 463億3380万 | -2.7% |
| 02/03 | 1,519 | 1,534 | 1,510 | 1,530 | +1.26% | 146,700 | 467億6169万 | -2.05% |
| 02/02 | 1,491 | 1,532 | 1,437 | 1,511 | -3.2% | 401,400 | 461億8099万 | -3.51% |
| 02/01 | （IR情報）15:00 組織改正、取締役・執行役員の担当職務委嘱変更および人事異動に関するお知らせ |
| 02/01 | （IR情報）15:00 通期連結業績予想の修正に関するお知らせ |
| 02/01 | （IR情報）15:00 2021年3月期第3四半期決算短信〔日本基準〕(連結) |
| 02/01 | 1,513 | 1,568 | 1,510 | 1,561 | +3.1% | 169,100 | 477億915万 | -0.7% |
| 01/29 | 1,549 | 1,563 | 1,506 | 1,514 | -2.26% | 96,900 | 462億7268万 | -3.87% |
| 01/28 | （IR情報）15:00 GnRHアンタゴニスト「レルミナ錠(レルゴリクスリクス)」子宮内膜症に対する効能効果の製造販売承認事項一部変更承認申請について |
| 01/28 | 1,521 | 1,563 | 1,500 | 1,549 | -0.06% | 139,800 | 473億4239万 | -2.02% |
| 01/27 | 1,573 | 1,578 | 1,546 | 1,550 | -0.26% | 59,100 | 473億7295万 | -2.45% |
| 01/26 | 1,585 | 1,587 | 1,536 | 1,554 | -1.58% | 94,000 | 474億9521万 | -2.69% |
| 01/25 | 1,542 | 1,582 | 1,536 | 1,579 | +3% | 131,100 | 482億5929万 | -1.62% |
| 01/22 | 1,525 | 1,538 | 1,516 | 1,533 | +0.52% | 86,500 | 468億5338万 | -4.9% |
| 01/21 | 1,527 | 1,555 | 1,523 | 1,525 | -0.59% | 78,400 | 466億887万 | -5.92% |
| 01/20 | 1,500 | 1,535 | 1,500 | 1,534 | +2.75% | 130,700 | 468億8394万 | -5.95% |
| 01/19 | 1,515 | 1,524 | 1,490 | 1,493 | -2.48% | 153,600 | 456億3085万 | -9.02% |
| 01/18 | 1,540 | 1,550 | 1,520 | 1,531 | -0.97% | 96,100 | 467億9225万 | -7.38% |
| 01/15 | （IR情報）15:00 Ha Tay Pharmaceutical Joint Stock Companyの株式取得完了のお知らせ |
| 01/15 | 1,591 | 1,591 | 1,543 | 1,546 | -3.44% | 143,200 | 472億5070万 | -7.2% |
| 01/14 | 1,620 | 1,628 | 1,594 | 1,601 | -0.62% | 140,800 | 489億3168万 | -4.59% |
| 01/13 | 1,663 | 1,665 | 1,606 | 1,611 | -2.19% | 128,500 | 492億3731万 | -4.67% |
| 01/12 | 1,634 | 1,653 | 1,602 | 1,647 | +3.32% | 153,900 | 503億3758万 | -3.06% |
| 01/08 | 1,575 | 1,595 | 1,564 | 1,594 | +2.38% | 169,900 | 487億1773万 | -6.57% |
| 01/07 | （IR情報）15:00 Harbin Pharmaceutical Group Co., Ltd.との中国国内の独占的販売権許諾契約締結のお知らせ |
| 01/07 | 1,596 | 1,596 | 1,552 | 1,557 | -0.38% | 126,500 | 475億8690万 | -9.16% |
| 01/06 | 1,592 | 1,595 | 1,560 | 1,563 | -0.7% | 138,700 | 477億7028万 | -9.13% |
| 01/05 | 1,580 | 1,580 | 1,557 | 1,574 | -0.44% | 85,200 | 481億647万 | -8.75% |
| 01/04 | 1,611 | 1,619 | 1,546 | 1,581 | -0.88% | 126,200 | 483億2041万 | -8.51% |
| 2020 |
| 12/30 | 1,615 | 1,618 | 1,595 | 1,595 | -0.68% | 105,200 | 487億4830万 | -7.86% |
| 12/29 | 1,581 | 1,609 | 1,581 | 1,606 | +0.37% | 133,100 | 490億8449万 | -7.22% |
| 12/28 | 1,626 | 1,646 | 1,591 | 1,600 | -2.38% | 120,500 | 489億111万 | -7.57% |
| 12/25 | 1,628 | 1,643 | 1,616 | 1,639 | -0.73% | 86,000 | 500億9308万 | -5.31% |
| 12/24 | 1,654 | 1,659 | 1,632 | 1,651 | -0.12% | 131,300 | 504億5984万 | -4.51% |
| 12/23 | 1,659 | 1,688 | 1,644 | 1,653 | -0.36% | 89,500 | 505億2096万 | -4.23% |
| 12/22 | 1,720 | 1,720 | 1,653 | 1,659 | -4.82% | 194,100 | 507億434万 | -3.77% |
| 12/21 | 1,787 | 1,793 | 1,725 | 1,743 | -1.02% | 127,700 | 532億7165万 | +1.22% |
| 12/18 | 1,740 | 1,764 | 1,719 | 1,761 | +1.27% | 116,300 | 538億2179万 | +2.56% |
| 12/17 | 1,750 | 1,751 | 1,716 | 1,739 | -1.81% | 145,500 | 531億4940万 | +1.64% |
| 12/16 | 1,756 | 1,789 | 1,753 | 1,771 | +1.66% | 109,200 | 541億2742万 | +3.75% |
| 12/15 | 1,778 | 1,779 | 1,741 | 1,742 | -2.41% | 93,900 | 532億4109万 | +2.53% |
| 12/14 | 1,782 | 1,817 | 1,782 | 1,785 | +0.22% | 156,300 | 545億5531万 | +5.56% |
| 12/11 | 1,793 | 1,798 | 1,754 | 1,781 | -1.22% | 196,400 | 544億3305万 | +5.89% |
| 12/10 | 1,832 | 1,839 | 1,798 | 1,803 | -2.96% | 140,300 | 551億544万 | +7.77% |
| 12/09 | 1,875 | 1,875 | 1,843 | 1,858 | +0.87% | 160,400 | 567億8642万 | +12.27% |
| 12/08 | 1,860 | 1,860 | 1,813 | 1,842 | -2.85% | 229,000 | 562億9741万 | +12.8% |
| 12/07 | （5%ルール）ゼリア新薬工業（3.84%） |
| 12/07 | 1,860 | 1,984 | 1,860 | 1,896 | +3.44% | 361,600 | 579億4782万 | +17.62% |
| 12/04 | 1,815 | 1,839 | 1,802 | 1,833 | +1.05% | 162,600 | 560億2234万 | +15.36% |
| 12/03 | 1,790 | 1,815 | 1,752 | 1,814 | +1% | 196,000 | 554億4164万 | +15.62% |
| 12/02 | 1,739 | 1,805 | 1,721 | 1,796 | +5.03% | 325,900 | 548億9150万 | +15.8% |
| 12/01 | 1,700 | 1,724 | 1,685 | 1,710 | +0.35% | 260,800 | 522億6307万 | +11.47% |
| 11/30 | 1,667 | 1,715 | 1,663 | 1,704 | +3.27% | 433,600 | 520億7969万 | +12.18% |
| 11/27 | 1,650 | 1,655 | 1,616 | 1,650 | +0.98% | 242,200 | 504億2927万 | +9.63% |
| 11/26 | 1,673 | 1,694 | 1,629 | 1,634 | +2.32% | 337,300 | 499億4026万 | +9.3% |
| 11/25 | （IR情報）15:00 GnRHアンタゴニストTAK-385(レルゴリクス)子宮内膜症患者を対象とした第3相比較試験結果のお知らせ |
| 11/25 | 1,620 | 1,626 | 1,596 | 1,597 | -1.18% | 130,200 | 488億942万 | +7.54% |
| 11/24 | （IR情報）15:00 執行役員および子会社役員の異動に関するお知らせ |
| 11/24 | 1,623 | 1,631 | 1,609 | 1,616 | +1.19% | 122,100 | 493億9012万 | +9.34% |
| 11/20 | 1,580 | 1,603 | 1,557 | 1,597 | +0.88% | 91,400 | 488億942万 | +8.71% |
| 11/19 | 1,577 | 1,592 | 1,548 | 1,583 | -0.25% | 106,700 | 483億8154万 | +8.28% |
| 11/18 | 1,608 | 1,614 | 1,580 | 1,587 | -1.31% | 165,000 | 485億379万 | +9% |
| 11/17 | 1,610 | 1,637 | 1,574 | 1,608 | -0.25% | 205,700 | 491億4562万 | +10.9% |
| 11/16 | 1,622 | 1,627 | 1,602 | 1,612 | -0.25% | 133,500 | 492億6787万 | +11.63% |
| 11/13 | 1,603 | 1,636 | 1,576 | 1,616 | +0.25% | 186,400 | 493億9012万 | +12.3% |
| 11/12 | 1,626 | 1,630 | 1,594 | 1,612 | -0.25% | 206,100 | 492億6787万 | +12.41% |
| 11/11 | 1,594 | 1,623 | 1,575 | 1,616 | +2.54% | 271,900 | 493億9012万 | +13.4% |
| 11/10 | 1,569 | 1,579 | 1,535 | 1,576 | +1.22% | 223,400 | 481億6760万 | +11.22% |
| 11/09 | 1,572 | 1,594 | 1,550 | 1,557 | -0.26% | 238,100 | 475億8690万 | +10.43% |
| 11/06 | 1,516 | 1,561 | 1,515 | 1,561 | +0.9% | 426,200 | 477億915万 | +11.18% |
| 11/05 | 1,500 | 1,548 | 1,459 | 1,547 | +14.76% | 921,800 | 472億8126万 | +10.66% |
| 11/04 | （IR情報）15:00 2021年3月期第2四半期決算短信(日本基準)(連結) |
| 11/04 | 1,345 | 1,358 | 1,322 | 1,348 | +2.43% | 88,300 | 411億9919万 | -3.3% |
| 11/02 | 1,300 | 1,339 | 1,300 | 1,316 | +0.46% | 109,100 | 402億2116万 | -5.87% |
| 10/30 | 1,333 | 1,336 | 1,300 | 1,310 | -1.87% | 95,100 | 400億3779万 | -6.63% |
| 10/27 | （IR情報）14:45 『女性のための働き方改革！「生理快適プロジェクト」』への協賛について |
| 10/26 | （IR情報）15:00 執行役員の担当職務委嘱変更および就任に関するお知らせ |
